Iambic Completes Dose Escalation in Ongoing Phase 1/1B Study of Lead Program IAM1363, a Small Molecule Inhibitor of Wild-Type and Oncogenic HER2 Mutant Proteins

Designed with Iambic’s AI-Drug Discovery platform, IAM1363 is highly differentiated by its target selectivity, brain-penetrance, pan-mutant activity, and tumor enrichment.

Call Now Button